Talimogene laherparepvec combined with neoadjuvant chemotherapy for non-metastatic triple negative breast cancer

Bookmark and Share
Published: 15 Apr 2019
Views: 668
Rating:
Save
Dr Hatem Soliman - Moffitt Cancer Centre, Tampa, USA

Dr Hatem Soliman speaks to ecancer at the 2019 American Association for Cancer Research (AACR) meeting about results from a study looking at the use of talimogene laherparepvec (TVEC) in combination with neoadjuvant chemotherapy for non-metastatic triple negative breast cancer.

He explains that the TVEC, an oncolytic virus modified to limit it's replication to in cancer cells, was incorporated with a taxane and anthracycline.

Dr Soliman reports that the combination was safe and feasible with no unexpected toxicities and that 55% of patients saw a complete eradication of the tumour from the breast.